Loading patent…
AssigneeIovance Biotherapeutics, Inc.
InventorsAnand Veerapathran, Aishwarya Gokuldass, Brian Rabinovich, Michael T. Lotze
Estimating the term…
In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-AB/C, ICOS-L, and CD58, and wherein the one or more viral vectors comprise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and/or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and/or OX40L proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs and methods of treating cancers using TILs after expansion with aAPCs are also disclosed.
An isolated artificial antigen presenting cell (aAPC) comprising an EM-3 myeloid cell that endogenously expresses ICOS-L (inducible T-cell co-stimulator ligand), CD58, and one or more of HLA (human leukocyte antigen)-A, HLA-B, or HLA-C, wherein said aAPC is stably transduced with one or more viral vectors, wherein the one or more viral vectors comprise:
An isolated artificial antigen presenting cell (aAPC) comprising an EM-3 cell that endogenously expresses ICOS-L (inducible T-cell co-stimulator ligand), CD58, and one or more of HLA-A, HLA-B, or HLA-C, wherein said aAPC is stably transduced with one or more viral vectors, wherein the one or more viral vectors comprise:
Dependencies are inferred from the claim text.